Phenotypic changes during cancer progression are associated to alterations in gene expression, which can be exploited to build molecular signatures for tumor stage identification and prognosis. However, it is not yet known whether the relative abundance of transcript isoforms may be informative for clinical stage and survival.
Introduction
Tumors advance through stages that are generally characterized by their size and spread to lymph nodes and other parts of the body [1] . Establishing the stage of a tumor is critical to determine patient prognosis and to select the appropriate therapeutic strategy [2] . Even though stage is generally defined from a number of tests carried out on a patient, this information may sometimes be incomplete or inconclusive. Advances in the molecular characterization of tumors have lead to improvements in stage classification and clinical management of patients [3] . Although tumors originate primarily from genetic lesions, their progression involves other molecular transformations, which are related to the activation of specific aggressive phenotypes, like tumor spread and metastasis, and are often reflected in gene expression changes [4, 5] . Accordingly, the development of gene expression signatures has been instrumental to complement and improve stage identification and prognosis [6] [7] [8] [9] . On the other hand, gene expression summarizes the output of RNA transcripts from a gene locus, which is mostly explained by one transcript isoform [10] . Furthermore, we described before how solid tumors present frequent changes in the relative abundances of isoforms in comparison to normal tissues [11] . This prompts the question of whether transcript isoform changes, which remain largely unexplored as predictive signatures of tumor stage and survival, could hold relevant novel mechanisms of tumor progression. We investigated the predictive potential of the relative abundances of transcript isoforms for tumor staging and clinical outcome in 12 different tumor types, integrating RNA sequencing and clinical annotation data for 12 tumor types from The Cancer Genome Atlas (TCGA) project. Our analyses revealed new signatures that characterize tumor phenotypes and their progression largely independent of gene expression. Knowledge about the relative abundance of transcript isoforms in tumors can potentially help predicting stage and clinical outcome and contribute towards current molecular strategies in precision cancer medicine.
Results

Relative abundances of transcript isoforms are predictive of tumor stage
We considered the standard clinical annotation for tumors based on the tumor size (T), lymph-node involvement (N) metastatic status (M) and combined stage (S), for 4339 patient samples from 12 different tumor types from TCGA (Additional file 1). For each tumor type, 6 We hypothesized that if the derived transcript signatures provide clinically relevant information, we should find worse clinical outcomes for patients predicted to be at late stage.
We thus performed a blind test on those samples that lacked stage annotation, and therefore were not used for building the models, to predict the tumor stage using the model for the corresponding tumor type ( Fig. 2a ) (Additional file 1). Additionally, we only performed the blind test in those tumor types for which late clinical stage was significantly associated to worse prognosis in the labeled samples ( Table 2 ). There were 40 samples from COAD, 116 from lung adenocarcinoma (LUAD) and 80 from BRCA that lacked M annotation. After prediction with the M-model from each tumor type, we obtained a total of 226 patients predicted as M0 and 10 patients predicted as M1. Aggregating patients according to the predicted metastatic class yielded a significant difference in survival between the two groups (p-value = 0.0079) ( Fig. 2c ). Regarding lymph node invasion, there were 1 sample from COAD, 10 from LUAD, 82 from KIRP, 247 from KIRC and 74 from HNSC without N annotation. After predicting with the N-models from the corresponding tumor types, 356 and 58 patients were predicted as early and late N, respectively. Survival analysis with the aggregated patients yielded a significant difference between the two predicted groups (p-value = 0.013) ( Fig. 2d ). Finally, for the S stage, we predicted on a set of 91 samples without S annotation (8 from COAD, 18 from BRCA, 47 from HNSC, 11 from KIRP, 4 from LUSC, 2 from THCA, and 1 from LUAD). This resulted in 47 and 44 samples predicted as early and late, respectively, which showed no difference in survival (p-value = 0.479). These results represent an independent validation of our transcript signatures and provide evidence that the relative abundances of transcripts can be predictive of tumor staging and prognosis.
No relation of isoform signatures with stromal and immune cell content
To assess whether the purity of the samples could a potential confounding factor of the derived signatures, we tested the correlation between the transcript PSI values of our predictive models against signatures of stromal and immune cell content [18] (Methods).
Overall, all signatures showed low correlation with stromal content (mean Pearson |R| < 0.4, Pearson), and all except the N-model in BRCA (Pearson R=0.433) had mean |R|<0.4 with immune cell content (Additional file 6). From the 547 transcript isoforms tested, 95% show a correlation |R|<0.4 (Pearson) for both stromal and immune scores. Among the few cases with |R|>0.5 there is an isoform of ENAH ( Fig. S2d in Additional file 2), which is present in the T-models in KIRP and COAD and that was previously linked to an invasive phenotype [19] .
Recent analyses have shown that clinical stage does not correlated with tumor purity in the TCGA samples [20] . Our analysis further supports those results and indicates that isoformbased signatures of stage do not reflect stromal or immune cell content.
No universal transcript isoform signature for tumor staging
Our results prompt the question of whether there might be a universal signature of stage and survival based on transcript isoform changes. To test this, we grouped all annotated samples from the different tumor types according to the stage class and applied the same analyses as before. We could only build M and S models due to the lack of common isoforms with discriminant power for the other classes (Additional file 7). The average AUC values for M and S models were lower than before, with mean AUC of 0.5 and 0.685, respectively.
Aggregating samples from BRCA, COAD and LUAD, we observed a slight increase in accuracy (mean AUC = 0.702). Similarly, analyzing KIRC, KIRP and KICH samples together, the S-model achieves mean AUC = 0.809. In this case, approximately half of the isoforms were present in the previous models. Finally, analyzing the squamous tumors together (HNSC and LUSC), we derived N and S models with mean AUC = 0.72. For other combinations, we could not find accuracies greater than AUC = 0.5. This indicates that despite some overlapping features across tumor types, there is no common signature for all the tested tumor types.
Transcript signatures provide better predictions than event-based signatures
We tested whether local alternative splicing events, as opposed to transcript isoform changes, could also be predictive of stage. We applied the same analysis pipeline using PSI values for all events in the same tumor samples. For most of the stage classes we observed similar or smaller accuracy values for events compared to transcript models (average AUC 0.617 vs. 0.778, respectively) ( Fig. 2d ) (Additional file 8). Only 23.5% of the isoforms in models overlap with at least one alternative splicing event from the event-based models: 16.51% overlap with alternative 5'/3' splice-sites, mutually exclusive exons, retained introns or cassette exon events, and 6.54% overlap with alternative first or last exon events. Moreover, 82.39% of isoforms in models overlap with at least one of the pre-calculated alternative splicing event. This indicates that a considerable number of changes in exon-intron structures described by the isoform models that are predictive of tumor stage cannot be captured in terms of simple alternative splicing events.
Transcript signatures provide relevant information about tumor metastasis and lymph node invasion independently of gene expression
Previously proposed molecular classifiers of stage were based on gene expression [7, 8] . We thus tested the relation of our transcript signatures with gene expression. We observed that the proportion of genes with differential expression vary markedly between transcript signatures (Additional file 5) (Methods). For M-models, 9 (18%) genes in the SKCM and 4 (18%) genes in KIRC showed differential expression. For N-models, we only found 3 (14%) in PRAD and 13 (68%) in THCA. In contrast, T-models presented frequent changes across the different tumor types, with 17 (46%) in KIRP, 7 (27%) in to KIRC, 6 (33%) in LUAD, 4 (50%) in THCA and 1 in HNSC (5%). Similarly, S-models also showed frequent DE: 16 (52%) in KIRC, 12 (46%) in KIRP, 1 (25%) in LUAD, and 1 (7%) in BRCA.
Next, we compared the predictive power of transcript and gene expression signatures. We thus applied our pipeline to gene expression values to derive gene-based signatures of stage (Methods). The overall accuracy for gene-based signatures was similar to isoform-based models (average AUC values 0.783 and 0.781 for isoforms and genes, respectively) ( in COAD S-models, and DNASE1L3 KICH S-models. Interestingly, gene-based S-models were predictive of survival for samples lacking stage S annotation (p-value = 0.0024) ( Fig.   2e ), whereas no significant difference in survival was found with the gene-based M and N models (p-values = 0.983 and 0.161, respectively).
The results described above suggest that genes and transcripts provide independent information and may yield better predictors when combined together. We thus built mixed models of gene expression and transcript relative abundance. We started with all gene and transcript discriminant features and selected a non-redundant set of features to build logisticmodel trees. The accuracy of these mixed models was on average better (mean AUC = 0.831) than using only transcripts or genes ( Finally, we compared our transcript signatures with an expression signature of 44 genes built to differentiate metastatic and late stage samples in colon cancer [21] (Methods). The mean AUC values obtained for the metastatic annotation (M) and the overall stage (S) were 0.612 and 0.649, respectively, for the gene expression signature, and 0.82 and 0.94, for our transcript signatures. Notably, none of the genes involved in our transcript models for COAD presented differential expression. Our analyses indicate that changes in the relative abundance of transcripts hold relevant information about tumor transformation independently of gene expression changes.
Transcript relative abundances as prognostic markers in ER-negative breast tumors
Molecular subtypes in cancer have implications for prognosis and therapy that go beyond the staging system [6, 22, 23] . In breast cancer, tumors that are negative for the Estrogen receptor (ER) have generally worse prognosis, and gene expression signatures are generally less accurate for ER negative than for ER positive tumors [3, 7] . To test whether transcript-based signatures could be relevant for ER negative tumors, we separated the samples according to the expression ranking of the ER gene (ESR1) into the top (ER+) and bottom (ER-) and 25% (237 samples each) ( Fig. 3a) . Interestingly, applying our pipeline we identified 2591 discriminant transcript isoforms between ER+ and ER-subgroups ( Fig. 3b ) (Additional file 9). These transcriptome changes were validated using RNA-Seq data from the knockdown of ESR1 and control in MCF7 cells [24] (Fig. S4a in Additional file 2) (Methods). We derived a predictive model with 81 discriminant transcripts that separated ER+ and ER-samples with an average AUC of 0.999 ( Fig. 3c ). Among the largest PSI changes we found an isoform of the MAP kinase MAP3K7, whose long isoform was linked before to apoptosis [25] , which we found to be less abundant in ER-samples ( Fig. S4b in Additional file 2). Notably, 47 (58%) of the genes with transcripts in this predictive model show differential expression, suggesting a link between estrogen receptor expression and the differential use of transcript isoforms.
The observed transcriptome differences between ER+ and ER-subtypes warrant a separation of these two sets to build transcript signatures of stage. Accordingly, we considered early and late stage patients in each ER group separately (Table 3 ). Since ER-samples show significant differences in survival between early and late stages for N (p-value = 0.005) and S (p-value = 0.041) annotations (Figs. S4c and S4d in Additional file 2), we expect that signature for stage may be relevant for prognosis. In contrast, ER+ samples do not show any significant differences in survival. Using our feature selection pipeline, we obtained 456 and 249 isoforms that best discriminate between early and late stages in the ER-and ER+ subsets, Notably, none of the derived signatures showed differential expression at the gene level.
Additionally, ER-S-model includes TNFRS8 (Fig. 3d ), a member of the tumor necrosis factor receptor superfamily. Another member of this family, TNFRSF17 was related before to prognosis in ER-samples [3] . Unlike for the previous models, there were not enough unlabeled samples to perform a blind test. Taken together, these results show that transcript variants can be informative for stage and prognosis in ER negative tumors.
We further compared our transcript signatures with known gene expression signatures for breast tumors: OncotypeDX [26] , MammaPrint [27], and PAM50 [28] (Methods). Although these signatures were not originally designed to identify tumor stage, they bear predictive value for this purpose [7] . Their accuracies to separate ER+ and ER-subgroups were very similar to our transcript signatures ( Fig. 3e ). This is expected for PAM50 and OncotypeDX, as they include ESR1. We then tested how well the gene signatures differentiate stage within each subset, ER+ or ER-, independently. In general, PAM50 performed better than the two other signatures, except for S in ER-and for N in ER+, where MammaPrint performs better, and for T in ER-, where OncotypeDX performs better ( Fig. 3e) . Notably, in all cases the transcript signature had better accuracies. We conclude that transcript isoform models can provide relevant information to determine stage and hence complement current clinical signatures.
Transcript relative abundances characterize an invasive phenotype and survival in melanoma
Clinical outcome of skin cutaneous melanoma (SKCM) remains poor due to its high degree of heterogeneity [29] . The microphthalmia-associated transcription factor (MITF) presents highly dynamic expression patterns in connection to proliferation and invasion in melanoma, with relevance for prognosis and therapy [30, 31] . Overexpression and downregulation of MITF have been connected to proliferative and invasive phenotypes, respectively [32] . We thus tested whether there are specific transcript signatures linked to these phenotypes that may be predictive of survival. We pooled the top and bottom 25% of melanoma samples according to MITF expression into the MITF+ and MITF-sets, respectively (96 samples per set) ( as well as for RAB27A, a component of the melanosome that is transcriptionally regulated by MITF [34] and that is lowly included in MITF+ samples ( Fig. S4d in Additional file 2). From this signature, 37 (66%) of the genes involved showed differential expression between MITF+ and MITF-subgroups, pointing to a link between MITF expression and differential usage of transcript isoforms in multiple genes.
To test whether the melanoma phenotypes are associated to different transcript transformations during tumor progression, we studied the MITF+ and MITF-sets (Fig. 4e ), which does not change expression at the gene level. MADD is a cancer driver and it was shown before that expression of isoforms that skip exon 16 has anti-apoptotic effects [35] . Interestingly, the PSI of the MADD isoform that skips exon 16 is higher in the group with worse prognosis, suggesting that the anti-apoptotic function of MADD is related to worse prognosis in invasive melanoma. Taken together, our results provide evidence of distinct transcript abundance patterns linked to melanoma phenotypes and survival.
Discussion
We described the first systematic analysis of the predictive potential of transcript relative abundances for stage and clinical outcome in multiple solid tumors. We derived novel molecular signatures for 12 different tumor types that can separate tumors according to clinical stage or metastatic status. Importantly, a blind test on patients with unknown stage or metastatic status can separate patients according to survival. Moreover, transcript isoforms provide better accuracies than local alternative splicing events and can describe more complex changes in exon-intron structures. Although a multi-cancer signature of clinical outcome based on gene expression has been proposed [36] , our results argue against a generic transcript-based signature for all tumors types. Rather, transcript isoform changes appear linked to tumor-type specific processes, with several of them related to MYC activity, in concordance with recent findings [37] .
We observed a widespread association between transcript isoform changes and expression changes in T and S models across tumor types, and around 60% of the genes with differential expression in all models correspond to KIRC and KIRP, indicating that transcript and gene changes are tightly coupled during progression of these tumors. In contrast, this association is low or absent for most tumor types for M and N models. The blind-test showing that patients with predicted metastasis or late N-stage predicted patients have a worse prognosis, was for tumor types for which none of these models show gene expression differences. The value of the transcript signatures is further highlighted when compared to known and newly derived gene expression signatures, or with mixed models combining gene expression and transcript abundances. These results indicate that transcripts signatures provide information independent from gene expression to describe tumor progression, and especially in metastasis and lymph node invasion.
We also extracted prognostic signatures for specific tumor subtypes in breast cancer and melanoma. We reported many significant transcript isoform changes between breast tumors according to estrogen receptor expression and between melanoma samples according to MITF expression. Additionally, we observed a widespread association between transcript isoform and expression changes between in relation to estrogen receptor expression and according to MITF expression. An interesting possibility is that the activity of these two transcription factor genes could trigger expression and transcript isoform changes in the same genes in these tumors, pointing to new mechanisms of gene regulation worth investigating further. We further derived transcript signatures of stage independently in each sample subset that involved different genes, thereby highlighting the relevance of determining the transcriptome repertoire in tumor samples to derive accurate molecular signatures of tumor progression.
We observed partial reproducibility of the discriminant isoforms in experiments using cell lines. Transcriptional differences between cell lines and tumor tissues are thought to stem from the loss of the stromal and immune components by cells in culture [38] . Our analyses discard an association between the transcript signatures and the composition of stromal and immune cells in the tissue samples. It could be possible that part of the signatures reflect the interaction of tumor cells with their environment in tissues samples, which would be undetectable in cell lines. Our results support the notion that phenotypic states of tumor cells, like invasiveness, may be reflected on the relative abundance of transcript isoforms, may be partly triggered by external cues, such as inflammation or metabolic stress [39] . On the other hand, the observed commonalities between tumor cells and tissues suggest that some of these alterations could be investigated further using cell lines.
It remains to be tested the clinical validity of our findings. Although we have shown that predicted late stages may be associated with worse prognosis and cross-fold validation shows better accuracies in general for transcript signatures, it is not conclusive whether the proposed molecular signatures would actually improve current methodologies of stage determination.
Our results indicate that isoform-based M and N models are generally accurate and often better than using gene expression. Those models may be especially useful, as they would indicate a metastasis or lymph node invasion before it is visible by other means. To test this, more validations on independent cohorts would be necessary. However, further studies are currently hampered by the scarcity of large enough datasets with clinical annotation comparable to TCGA [40] . Moreover, the current accuracies of the transcript models may require a larger number of samples to perform prospective studies. Nonetheless, we anticipate that transcript isoforms will be relevant to understand the progression of tumors beyond DNA and gene expression alterations and represent useful novel targets to predict stage and clinical outcome, thereby complementing current molecular approaches in precision cancer medicine.
Methods
Datasets
Processed RNA sequencing data from The Cancer Genome Atlas (TCGA) (https://tcgadata.nci.nih.gov/tcga/) was compiled for 12 different tumor types: breast carcinoma (BRCA), counts and the isoform lengths. Genes were defined to be a set of transcripts that overlap in the same genomic locus and strand and share at least one splice-site (Additional file 1). A gene TPM was defined as the sum of TPMs for all transcripts in the gene. The relative abundance of each isoform (PSI), was calculated by normalizing the isoform TPM to the gene TPM. Only genes with a minimum TPM of 0.1 were considered. Additionally, we used RNA-Seq data from the knockdown of ESR1 and controls in MCF7 cells (GSE53533) [24] , from metastatic melanoma cells (SKMel147) and melanocytes (GSE68221) [12] , and from the knockdown of MITF and controls using non-metastatic melanoma cells (Mel505) (GSE61967) [13] . For each sample, transcript abundances were calculated with Sailfish [41] .
Relative abundances (PSI) of transcripts were calculated as above and the ΔPSI values between conditions were calculated as the difference between conditions of the mean values from the replicates. Alternative splicing events and their PSI values were obtained from [42] .
Clinical data
Clinical stage and survival information for patients was obtained from TGCA. We used the available annotation for the TNM staging system (www.cancerstaging.org/), where T followed by a number (1-4) describes the size of the tumor; N followed by a number (1-3) describes spread to lymph nodes according to number and distance; and M followed by 1 or 0 indicates whether the tumor has metastasized or not, respectively. We also considered the numbered stage annotation (S), which goes from 0 to 4, with each number corresponding approximately to a combination of the TNM numbers. When any of the stages were subdivided, only the label of the common class was included (e.g. T1a, T1b and T1c were considered as T1). Only patients with defined stage were used to build the predictive models.
Selection of relevant features
Only isoforms and events with a difference in mean relative abundance (PSI) of at least 0.1 in absolute value between the compared patient subgroups were considered to calculate discriminant isoforms. To obtain discriminant genes, those with log-fold change of the mean gene TPM values between the two groups greater than 2 were considered. Next, a subsampling approach was used to compare two patient groups through 100 iterations, by extracting the same number of samples from each group randomly from the input dataset, using a minimum of 10 samples per group. For pooled tumor types, the same number of samples per tumor type was selected at each iteration step. At each iteration step, three different univariate discriminant measures were applied (see below), and a permutation of the group labels was performed and the univariate measures re-calculated. After 100 iterations, and for each univariate measure, two distributions of 100 points each are produced for each transcript, corresponding to the observed and expected values. Transcripts with a positive difference of the means of the two distributions for all three measures were considered discriminant and were kept for further analysis.
We applied the following information-based measures in the subsampling: information gain (IG), gain ratio (GR) and symmetrical uncertainty (SU). IG is defined as the mutual [43] . The group labels are the clinical stages (early, late), survival groups (low, high), or phenotype group (invasive, proliferative); and the attribute values are the PSI values for transcript isoforms or alternative splicing events, or the gene TPM values for gene expression analyses. The continuous PSI or TPM values were discretized as previously described [44] .
Cancer hallmarks and drivers
Enrichment analysis of the 50 cancer hallmarks from the Molecular Signatures Database v4.0 [45] was performed with the discriminant isoforms. For each hallmark, a Fisher exact test was performed with the genes with selected isoforms using as controls genes expressed (TPM>0.1) and with multiple transcripts A Benjamini-Hochberg correction was applied and only cases with FDR < 0.05 were kept. Known and predicted cancer drivers were obtained as described in [42] .
Predictive signatures
Transcript isoforms that showed a positive difference between the means of the 100 observed and the 100 randomized values for all three univariate measures (IG, GR, SU) were analyzed with a Correlation Feature Selection (CFS) (Hall 2000) . This selects transcripts with similar discriminating power but lower redundancy among them (Hall 2000) , thereby mitigating the problem of overfitting. This was repeated for each comparison between clinical stages, survival groups, or tumor subtypes. Using the selected transcript isoforms, a Logistic Model Tree (LMT) was built with Rweka [46] . LMTs are classification trees with logistic regression functions at the leaves. The accuracy of the classifiers was evaluated using the area under the receiver-operating characteristic (ROC) curve or AUC. Additionally, we considered the area under the precision-recall curve (PRC). AUC and PRC take values between 0 (worst prediction) and 1 (best prediction). These values were estimated for each classifier through a 10-fold cross validation, repeated 100 times. The same approach was used for gene, event, and mixed models. To apply known gene expression signatures to our sample groups we used robust Z-scores per gene and per sample as described before [42] . These values were the used for the genes in various signatures [21, 26, 27, 28] . As before, accuracies were estimated using a 10-fold cross-validation to calculate AUC and PRC values.
Blind tests
For samples without stage annotation, which were not used to build the models, we predicted the missing stage (early/late) or metastatic state, using the corresponding model for the same tumor type. These newly predicted samples were then aggregated per clinical class according early and late, or metastatic and non-metastatic, to test the survival differences between groups. The blind test was performed using only those tumor types that already showed significant differences in the survival between early and late stages for the annotated samples (Table 2 ). This analysis was not performed for T-models, as all samples had a T annotation.
Differential expression analysis
We performed differential expression (DE) analysis for all genes between the different groups considered in this analysis, using the same method as described previously [41] . Genes were considered differentially expressed if the absolute value of the log2-fold change was greater than 0.5 and corrected p-value < 0.05. Results can be found in Additional_files_6 and 10.
Survival analysis
Survival curves were calculated with the Kaplan-Meier method and compared between patient subsets using a Cox proportional hazards regression model [47] . Survival was measured as date of death minus collection date for deceased patients and as last contact date minus collection date for the other patients.
Stromal and Immune cell content analysis
To estimate a stromal and immune signature for a set of samples from a tumor type, we collected a list of stromal and immune signature genes based on [18] . We transformed the RSEM read counts of these two gene lists into a gene set score using GSVA [48] for each sample. Using the resulting scores per sample, we then calculated the Pearson correlations of the stromal and immune GSVA scores with the transcript isoform PSIs using all tumor samples, including intermediate stages. The number of samples used for the comparison early vs late are indicated for each annotation T, N, M, S. Stages I, II, III and IV are indicated as S1, S2, S3 and S4. Comparisons were performed between the earliest and latest available stage groups, with some exceptions for which adjacent stages were added to have enough samples for comparison. Empty cells correspond to cases not tested due to lack of sufficient samples or complete lack of annotation in the samples. cases not tested due to lack of sufficient samples (see Table 1 ). The number of samples used for the comparison early vs late are indicated for each annotation T, N ans S. Stages I, II, III and IV are indicated as S1, S2, S3 and S4. In some cases, more than one clinical stage is included in a patient group to have sufficient samples. Due to the insufficient number of annotated samples, it was not possible to build M-models. Given two patient groups, we subsampled two equal sized subsets, one from each group (e.g. metastatic and non-metastatic), which were compared using information-based measures, denoted as I iso . At each iteration step, the group labels were randomized to obtain an expected measure, denoted as I rand . After 100 iterations, two distributions were produced for each . 
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